The 36-month beta value for BCRX is at 1.06. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 5 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for BCRX is 197.52M, and currently, shorts hold a 9.26% of that float. The average trading volume for BCRX on May 12, 2025 was 4.42M shares.
BCRX) stock’s latest price update
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) has seen a rise in its stock price by 0.50 in relation to its previous close of 9.92. However, the company has experienced a 11.65% gain in its stock price over the last five trading sessions. zacks.com reported 2025-05-09 that BCRX, WYY and RMBS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 9, 2025.
BCRX’s Market Performance
BCRX’s stock has risen by 11.65% in the past week, with a monthly rise of 47.27% and a quarterly rise of 14.33%. The volatility ratio for the week is 7.95% while the volatility levels for the last 30 days are 5.87% for Biocryst Pharmaceuticals Inc The simple moving average for the past 20 days is 17.07% for BCRX’s stock, with a 26.93% simple moving average for the past 200 days.
Analysts’ Opinion of BCRX
Many brokerage firms have already submitted their reports for BCRX stocks, with Cantor Fitzgerald repeating the rating for BCRX by listing it as a “Overweight.” The predicted price for BCRX in the upcoming period, according to Cantor Fitzgerald is $20 based on the research report published on April 29, 2025 of the current year 2025.
Wedbush, on the other hand, stated in their research note that they expect to see BCRX reach a price target of $15. The rating they have provided for BCRX stocks is “Outperform” according to the report published on February 25th, 2025.
JP Morgan gave a rating of “Overweight” to BCRX, setting the target price at $10 in the report published on November 20th of the previous year.
BCRX Trading at 25.15% from the 50-Day Moving Average
After a stumble in the market that brought BCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.26% of loss for the given period.
Volatility was left at 5.87%, however, over the last 30 days, the volatility rate increased by 7.95%, as shares surge +55.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.71% upper at present.
During the last 5 trading sessions, BCRX rose by +11.65%, which changed the moving average for the period of 200-days by +33.47% in comparison to the 20-day moving average, which settled at $8.52. In addition, Biocryst Pharmaceuticals Inc saw 32.58% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCRX starting from Hutson Nancy J, who sale 7,000 shares at the price of $7.54 back on Dec 13 ’24. After this action, Hutson Nancy J now owns 86,638 shares of Biocryst Pharmaceuticals Inc, valued at $52,780 using the latest closing price.
Hutson Nancy J, the Director of Biocryst Pharmaceuticals Inc, proposed sale 7,000 shares at $7.51 during a trade that took place back on Dec 13 ’24, which means that Hutson Nancy J is holding shares at $52,584 based on the most recent closing price.
Stock Fundamentals for BCRX
Current profitability levels for the company are sitting at:
- 0.07 for the present operating margin
- 0.97 for the gross margin
The net margin for Biocryst Pharmaceuticals Inc stands at -0.11. The total capital return value is set at 0.07.
Currently, EBITDA for the company is 12.81 million with net debt to EBITDA at -7.74. When we switch over and look at the enterprise to sales, we see a ratio of 3.52. The receivables turnover for the company is 5.39for trailing twelve months and the total asset turnover is 1.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.93.
Conclusion
In conclusion, Biocryst Pharmaceuticals Inc (BCRX) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
